갑상선 종양의 발병 기전

키워드

참고문헌 (72)

1. Russo D, "Genetic alterations in thyroid hyperfunctioning adenomas", J Clin Endocrinol Metab, 80, pp.1347~1351 (1995)
2. Krohn K, "Somatic mutations in thyroid nodular disease", Mol Genet Metab, 75, pp.202~208 (2002)
3. Nikiforova MN, "Molecular diagnostics and predictors in thyroid cancer", Thyroid, 19, pp.1~11 (2009)
4. Delellis RA, "Pathology and genetics of thyroid carcinoma", J Surg Oncol, 94, pp.662~669 (2006)
5. Greco A, "Molecular pathology of differentiated thyroid cancer", Q J Nucl Med Mol Imaging, 53, pp.440~453 (2009)
6. Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
7. Chiosea S, "A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma", Endocr Pathol, 20, pp.122~126 (2009)
8. Ciampi R, "Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer", J Clin Invest, 115, pp.94~101 (2005)
9. Knauf JA, "Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation", Cancer Res, 65, pp.4238~4245 (2005)
10. Nikiforova MN, "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", J Endocrinol Metab, 88, pp.5399~5404 (2003)
11. Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
12. Fusco A, "A new oncogene in human papillary carcinomas and their lymph nodal metastases", Nature, 328, pp.170~172 (1987)
13. Grieco M, "PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human papillary thyroid carcinomas", Cell, 60, pp.557~563 (1990)
14. Viglietto G, "RET", PTC oncogene activation is an early event in thyroid carcinogenesis, 1995, pp.11, 1207~1210
15. Fischer AH, "Papillary thyroid carcinoma oncogene (RET", PTC) alters the nuclear envelope and chromatin structure, 1998, pp.153, 1443~1450
16. Jhiang SM, "Targeted expression of the ret", PTC1 oncogene induces papillary thyroid carcinomas, 1996, pp.137, 375~378
17. Santoro M, "Development of thyroid papillary carcinomas secondary to tissue specific expression of the RET", PTC1 oncogene in transgene mice, 1996, pp.12, 1821~1826
18. Nikiforov Y, "RET", PTC rearrangement in thyroid tumors, 2002, pp.13, 3~16
19. Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
20. Nikiforov YE, "Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children", Cancer Res, 57, pp.1690~1694 (1997)
21. Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
22. Capella G, "Ras oncogene mutations in thyroid tumors: Polymerase chain reaction restriction-fragment-length polymorphism analysis from paraffin embedded tissue", Diagn Mol Pathol, 5, pp.45~52 (1996)
23. Di Cristofaro J, "Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: Association of N-ras mutation in codon 61 with follicular variant", Hum Pathol, 37, pp.824~830 (2006)
24. Rabes HM, "Pattern of radiation induced RET and NTRK rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: Biological, phenotypic and clinical implications", Clin Cancer Res, 6, pp.1093~1103 (2000)
25. Russell JP, "The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium", Oncogene, 19, pp.5729~5735 (2000)
26. Xing M, "Gene methylation in thyroid tumorigenesis", Endocrinology, 148, pp.948~953 (2007)
27. Bartel DP, "MicroRNAs: genomics, biogenesis, mechanism, and function", Cell, 116, pp.281~297 (2004)
28. Nikiforova MN, "MicroRNA expression profiles in thyroid tumors", Endocr Pathol, 20, pp.85~91 (2009)
29. Nikiforova MN, "RAS point mutations and PAX8- PPARg rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma", J Clin Endocrinol Metab, 88, pp.2318~2326 (2003)
30. Schark C, "N-ras 61 oncogene mutations in Hurthle cell tumors", Surgery, 108, pp.994~999 (1990)
31. Kebebew E, "Thyroid oncogenesis. In:Textbook of Endocrine Surgery. 2nd ed.", pp.289~ (2005), Elsevier Saunders
32. Pasca di Magliano M, "Pax8 has a key role in thyroid cell differentiation", Proc Natl Acad Sci U.S.A, 97, pp.13144~13149 (2000)
33. Wang T, "Peroxisome proliferator-activated receptor gamma in malignant diseases", Crit Rev Oncol Hematol, 58, pp.1~14 (2006)
34. Kroll TG, "PAX8- PPARg 1 fusion oncogene in human thyroid carcinoma", Science, 289, pp.1357~1360 (2000)
35. Nikiforova MN, "RAS point mutations and PAX8- PPARg rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma", J Clin Endocrinol Metab, 88, pp.2318~2326 (2003)
36. Lui WO, "CREB3L2-PPARg fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis", Cancer Res, 68, pp.7156~7164 (2008)
37. Yin Y, "Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification", Cancer Res, 69, pp.687~694 (2009)
38. French CA, "Genetic and biological subgroups of low stage follicular thyroid cancer", Am J Pathol, 162, pp.1053~1060 (2003)
39. Liaw D, "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome", Nat Genet, 16, pp.64~67 (1997)
40. Chen ML, "The deficiency of Akt1 is sufficient to suppress tumor development in PTEN+", − mice, 2006, pp.20, 1569~1574
41. Paes JE, "Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia", Endocrinol Metab Clin North Am, 37, pp.375~387 (2008)
42. Weber F, "A limited set of human microRNAs is deregulated in follicular thyroid carcinoma", J Clin Endocrinol Metab, 91, pp.3584~3591 (2006)
43. Sobrinho-Simões M, "Hurthle (oncocytic) cell tumors of thyroid: Etiopathogenesis, diagnosis and clinical significance", Int J Surg Pathol, 13, pp.29~35 (2005)
44. Máximo V, "Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNAvariants in human thyroid pathology: A study with emphasis on Hurthle cell tumors", Am J Pathol, 160, pp.1857~1865 (2002)
45. Máximo V, "Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid", Br J Cancer, 9, pp.1892~1898 (2005)
46. Masood S, "Differential oncogenic expression in thyroid follicular and H-rthle cell carcinomas", Am J Surg, 166, pp.366~368 (1993)
47. Sakamoto A, "Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high risk group of papillary and follicular carcinomas", Cancer, 52, pp.1849~1855 (1983)
48. Santoro M, "RET activation and clinicopathologic features in poorly differentiated thyroid tumors", J Clin Endocrinol Metab, 87, pp.370~379 (2002)
49. Santarpia L, "Phosphatidylinositol 3-kinase", akt and ras, J Clin Endocrinol Metab, pp.2008, 93[DOI]
50. Ito T, "Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland", Cancer Research, 52, pp.1369~1371 (1992)
51. Garcia-Rostan G, "Beta-catenin dysregulation in thyroid neoplasms: downregulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis", Am J Pathol, 158, pp.987~996 (2001)
52. Ricarte-Filho JC, "Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1", Cancer Research, 69, pp.4885~4893 (2009)
53. LaPerle KM, "Loss of p53 promotes anaplasia and local invasion in ret", PTC1-induced thyroid carcinomas, 2000, pp.157, 671~677
54. Visone R, "Specific microRNAs are downregulated in human thyroid anaplastic carcinomas", Oncogene, 26, pp.7590~7595 (2007)
55. Zhu H, "Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells", Autophagy, 5, pp.816~823 (2009)
56. Biunno I, "SEL1L a multifaceted protein playing a role in tumor progression", J Cell Physiol, 208, pp.23~38 (2006)
57. Kota J, "Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model", Cell, 137, pp.1005~1017 (2009)
58. Mitomo S, "Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines", Cancer Science, 99, pp.280~286 (2008)
59. Takakura S, "Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells", Cancer Science, 99, pp.1147~1154 (2008)
60. Hemminki K, "Familial risk of cancer by site and histopathology", Int J Cancer, 103, pp.105~109 (2003)
61. Foulkes WD, "Familial non-medullary thyroid cancer. In:Pathology and Genetics of Tumours of Endocrine Organs.", pp.257~261 (2004), IARC Press
62. Lesueur F, "Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium", J Clin Endocrinol Metab, 84, pp.2157~2162 (1999)
63. McKay JD, "Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21", Am J Hum Genet, 69, pp.440~446 (2001)
64. Adjadj E, "Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancer", Lancet Oncol, 10, pp.181~190 (2009)
65. Santoro M, "Dysfunction of the RET receptor in human cancer", Cell Mol Life Sci, 61, pp.2954~2964 (2004)
66. Kawai K, "Tissue specific carcinogenesis in transgenic mice expressing the RET protooncogene with a multiple endocrine neoplasia type 2A mutation", Cancer Res, 60, pp.5254~5260 (2000)
67. Wohllk N, "Relevance of RET protooncogene mutations in sporadic medullary thyroid carcinoma", J Clin Endocrinol Metab, 81, pp.3740~3745 (1996)
68. Ponder BAJ, "Multiple endocrine neoplasia type 2. In:The Metabolic and Molecular Basis of Inherited Disease. 8th ed.", pp.931~942 (2001), McGraw-Hill
69. Brandi ML, "Guidelines for diagnosis and therapy of MEN type 1 and type 2", J Clin Endocrinol Metab, 86, pp.5658~5667 (2001)
70. Thieblemont C, "Primary thyroid lymphoma is a heterogeneous disease", J Clin Endocrinol Metab, 87, pp.105~111 (2002)
71. Hyjek E, "Primary B-cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis", Hum Pathol, 19, pp.1315~1326 (1988)
72. Takano T, "Fetal cell carcinogenesis of the thyroid: Theory and practice", Semin Cancer Biol, 17, pp.233~240 (2007)

관련 논문AI추천